Newer rheumatoid arthritis drugs work well in the real world
They’ve been approved in the US since 2012, but Janus kinase (JAK) inhibitors are still the new kid on the block in terms of rheumatoid arthritis treatment. A new study lays to rest the doubts some had over their effectiveness beyond clinical trials. Source of Article